Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 6/2021

01-12-2021 | Gastrointestinal Amyloidosis | Case Report

Gastrointestinal AA amyloidosis secondary to chronic pyelonephritis presenting with refractory diarrhea and severe hypoalbuminemia

Authors: Tomoko Tanaka, Tatsushi Naito, Yohei Midori, Takuto Nosaka, Kazuto Takahashi, Kazuya Ofuji, Hidetaka Matsuda, Masahiro Ohtani, Katsushi Hiramatsu, Yoshiaki Imamura, Osamu Yokoyama, Hironobu Naiki, Yasunari Nakamoto

Published in: Clinical Journal of Gastroenterology | Issue 6/2021

Login to get access

Abstract

Secondary amyloidosis is a rare complication of chronic inflammatory diseases, such as collagen diseases, and is often difficult to treat. In addition, the gastrointestinal tract is frequently involved in amyloid deposition that often results in various disorders and symptoms. A 70-year-old woman was admitted to our hospital with refractory diarrhea and hypoalbuminemia. Abdominal computed tomography demonstrated extensive edematous wall thickening of the small intestine and colon. Video capsule endoscopy revealed multiple ulcerations with a white mossy appearance of the ileum. Double-balloon endoscopy showed severe circumferential ulcers in the entire ileum. Histological examination of ileum biopsy samples revealed severe amyloid deposition in the lamina propria and perivascular areas of the submucosa. The patient was diagnosed with gastrointestinal AA amyloidosis. The cause of AA amyloid deposition was presumed to be chronic pyelonephritis due to ureteral stones that had been left untreated for 35 years. After treatment with ureteral drainage and antibiotics, the patient’s symptoms and serological abnormalities improved dramatically. Here, we describe a case of severe gastrointestinal AA amyloidosis secondary to chronic pyelonephritis. Clinicians should thoroughly investigate the entire gastrointestinal tract in patients with refractory diarrhea and severe hypoalbuminemia considering the possibility of gastrointestinal amyloidosis.
Literature
1.
go back to reference Choi JH, Ko BM, Kim C, et al. A case of localized amyloid light-chain amyloidosis in the small intestine. Intest Res. 2014;12:245–50.CrossRef Choi JH, Ko BM, Kim C, et al. A case of localized amyloid light-chain amyloidosis in the small intestine. Intest Res. 2014;12:245–50.CrossRef
2.
go back to reference Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103:776–87.CrossRef Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103:776–87.CrossRef
3.
go back to reference Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int. 2020;70:191–8.CrossRef Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int. 2020;70:191–8.CrossRef
4.
go back to reference Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98:141–6.CrossRef Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98:141–6.CrossRef
5.
go back to reference Shiratori Y, Fukuda K, Ikeya T, et al. Primary gastrointestinal amyloidosis with gastrointestinal hemorrhage and intestinal pseudo-obstruction: a report of a rare case. Clin J Gastroenterol. 2019;12:258–62.CrossRef Shiratori Y, Fukuda K, Ikeya T, et al. Primary gastrointestinal amyloidosis with gastrointestinal hemorrhage and intestinal pseudo-obstruction: a report of a rare case. Clin J Gastroenterol. 2019;12:258–62.CrossRef
6.
go back to reference Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views. J Gastroenterol Hepatol. 2018;33:583–90.CrossRef Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views. J Gastroenterol Hepatol. 2018;33:583–90.CrossRef
7.
go back to reference Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc. 1994;40:45–50.CrossRef Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc. 1994;40:45–50.CrossRef
9.
go back to reference Gal R, Korzets A, Schwartz A, et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med. 1994;118:718–21.PubMed Gal R, Korzets A, Schwartz A, et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med. 1994;118:718–21.PubMed
10.
go back to reference Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.CrossRef Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.CrossRef
11.
go back to reference Tsuchiya Y, Ubara Y, Suwabe T, et al. AA-amyloidosis in autosomal dominant polycystic kidney disease caused by chronic cyst infections lasting for 30 years. Intern Med. 2013;52:791–4.CrossRef Tsuchiya Y, Ubara Y, Suwabe T, et al. AA-amyloidosis in autosomal dominant polycystic kidney disease caused by chronic cyst infections lasting for 30 years. Intern Med. 2013;52:791–4.CrossRef
12.
go back to reference Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.CrossRef Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.CrossRef
13.
go back to reference Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis. 2016;2:10–9.CrossRef Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis. 2016;2:10–9.CrossRef
Metadata
Title
Gastrointestinal AA amyloidosis secondary to chronic pyelonephritis presenting with refractory diarrhea and severe hypoalbuminemia
Authors
Tomoko Tanaka
Tatsushi Naito
Yohei Midori
Takuto Nosaka
Kazuto Takahashi
Kazuya Ofuji
Hidetaka Matsuda
Masahiro Ohtani
Katsushi Hiramatsu
Yoshiaki Imamura
Osamu Yokoyama
Hironobu Naiki
Yasunari Nakamoto
Publication date
01-12-2021
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 6/2021
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-021-01508-1

Other articles of this Issue 6/2021

Clinical Journal of Gastroenterology 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine